Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization
- PMID: 36097737
- PMCID: PMC9468693
- DOI: 10.5653/cerm.2021.05057
Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization
Abstract
Objective: Platelet-rich plasma (PRP) therapy has received a considerable attention as an adjunct to fertility treatments, especially in women with very low ovarian reserve and premature ovarian insufficiency. Although recent studies have demonstrated that PRP led to improvements in folliculogenesis and biomarkers of ovarian reserve, the effect of intraovarian PRP administration on embryo genetics has not been studied.
Methods: We report a pilot study of patients who had preimplantation genetic testing for aneuploidy (PGT-A) before and then within 3 months following PRP administration. Twelve infertile women with at least one prior failed in vitro fertilization (IVF) cycle underwent ovarian stimulation (cycle 1) with a gentle stimulation protocol and PGT-A performed at the blastocyst stage. Following cycle 1, autologous intraovarian PRP administration was performed. Within 3 months following PRP administration, the patients underwent cycle 2 and produced blastocysts for PGT-A. The percentage of euploid embryos between both cycles was compared.
Results: The mean age of all participants was 40.08±1.46 years, and their mean body mass index was 26.18±1.18 kg/m2. The number of good-quality embryos formed at the blastocyst stage was similar between cycle 1 and cycle 2 (3.08±0.88 vs. 2.17±0.49, respectively; p=0.11). Among all patients in cycle 1, 3 of 37 embryos were euploid (8.11%) while in cycle 2, 11 out of 28 embryos were euploid (39.28%, p=0.002). Three clinical pregnancies were noted among this patient group.
Conclusion: This novel study is the first to present an improvement in the embryo euploidy rate following intraovarian PRP application in infertile women with prior failed IVF cycles. The growth factors present in PRP may exhibit a local paracrine effect that could improve meiotic aberrations in human oocytes and thus improve euploidy rates. Whether PRP improves live birth rates and lowers miscarriage rates remains to be determined in large trials.
Keywords: In vitro fertilization; Ovary; Platelet-rich plasma; Preimplantation genetic testing.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Similar articles
-
Effect of intraovarian platelet-rich plasma injection on IVF outcomes in women with poor ovarian response: the PROVA randomized controlled trial.Hum Reprod. 2024 May 9:deae093. doi: 10.1093/humrep/deae093. Online ahead of print. Hum Reprod. 2024. PMID: 38725194
-
Leave the past behind: women's reproductive history shows no association with blastocysts' euploidy and limited association with live birth rates after euploid embryo transfers.Hum Reprod. 2021 Mar 18;36(4):929-940. doi: 10.1093/humrep/deab014. Hum Reprod. 2021. PMID: 33608730
-
First PGT-A using human in vivo blastocysts recovered by uterine lavage: comparison with matched IVF embryo controls†.Hum Reprod. 2020 Jan 1;35(1):70-80. doi: 10.1093/humrep/dez242. Hum Reprod. 2020. PMID: 31886877 Free PMC article.
-
The cytogenetic constitution of human blastocysts: insights from comprehensive chromosome screening strategies.Hum Reprod Update. 2019 Jan 1;25(1):15-33. doi: 10.1093/humupd/dmy036. Hum Reprod Update. 2019. PMID: 30395265 Review.
-
Ovarian response to intraovarian platelet-rich plasma (PRP) administration: hypotheses and potential mechanisms of action.J Assist Reprod Genet. 2022 Jan;39(1):37-61. doi: 10.1007/s10815-021-02385-w. Epub 2022 Feb 17. J Assist Reprod Genet. 2022. PMID: 35175511 Free PMC article. Review.
Cited by
-
Current Status and Future Prospects of Stem Cell Therapy for Infertile Patients with Premature Ovarian Insufficiency.Biomolecules. 2024 Feb 19;14(2):242. doi: 10.3390/biom14020242. Biomolecules. 2024. PMID: 38397479 Free PMC article. Review.
-
Multichannel Recovery Potential with Activated Autologous Intraovarian Platelet-Rich Plasma and Its Derivatives.Medicines (Basel). 2023 Jul 3;10(7):40. doi: 10.3390/medicines10070040. Medicines (Basel). 2023. PMID: 37505061 Free PMC article.
-
Beneficial effects of intraovarian injection of platelet-rich plasma in women with poor ovarian response.Clin Exp Reprod Med. 2023 Dec;50(4):285-291. doi: 10.5653/cerm.2023.06086. Epub 2023 Oct 24. Clin Exp Reprod Med. 2023. PMID: 37995757 Free PMC article.
-
Transcriptomic landscape of cumulus cells from patients <38 years old with a history of poor ovarian response (POR) treated with platelet-rich plasma (PRP).Aging (Albany NY). 2025 Feb 18;17(2):431-447. doi: 10.18632/aging.206202. Epub 2025 Feb 18. Aging (Albany NY). 2025. PMID: 39976580 Free PMC article.
-
Intraovarian PRP injection improves oocyte quality and early embryo development in mouse models of chemotherapy-induced diminished ovarian reserve.Aging (Albany NY). 2024 Sep 13;16(17):12123-12137. doi: 10.18632/aging.206099. Epub 2024 Sep 13. Aging (Albany NY). 2024. PMID: 39276378 Free PMC article.
References
-
- Labarta E, de Los Santos MJ, Escriba MJ, Pellicer A, Herraiz S. Mitochondria as a tool for oocyte rejuvenation. Fertil Steril. 2019;111:219–26. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials